Abstracts tagged "Mouse Models, Other"

Abstract Number: 0173 • ACR Convergence 2020
mTORC1 Signaling Promotes Monocytosis and Arthritis Development in IL-1 Receptor Antagonist-deficient Mice
Zhengping Huang¹, Ying Li², Alexandra Wactor³, Peter Nigrovic⁴ and Pui Lee⁵, ¹1.Guangdong Second Provincial General Hospital;2.Brigham and Women's Hospital;3.Harvard Medical School, BOSTON, MA, ²1.Brandeis University;2.Brigham and Women's Hospital, Waltham, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, ⁵1.Boston Children's Hospital;2.Brigham and Women's Hospital;3.Harvard Medical School, Newton, MA
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is potentially life-threatening disease characterized by prolonged fever, systemic inflammation and skin rash in addition to joint inflammation. Aberrant…
Abstract Number: 0469 • ACR Convergence 2020
IFNγ Is Essential for Alveolar Macrophage Driven Lung Inflammation in Macrophage Activation Syndrome
Denny Gao¹, Maggie Henderlight¹, Christopher Woods¹, Alexei Grom¹, Sherry Thornton¹, Michael Jordan¹, Katheryn Wikenheiser-Brokamp¹ and Grant Schulert², ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening cytokine storm syndrome frequently complicating systemic juvenile idiopathic arthritis (SJIA) and driven by IFNγ. MAS is also…
Abstract Number: 0703 • ACR Convergence 2020
Liraglutide as a Potential Intra-Articular Treatment for Cartilage Regeneration in Osteoarthritis: In Vitro and In Vivo Studies Supporting a Pro-Chondrogenic Effect
Francis Berenbaum¹, Coralie Meurot², Laure Sudre³, Keren Bismuth², Revital Rattenbach², Patrice Denefle², Celine Martin² and Claire Jacques³, ¹AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, ²Campus Institut Pasteur Lille, 4P Pharma, Lille, France, ³Inserm, UMR_S938, Hospital Saint-Antoine, Paris, France
Background/Purpose: Osteoarthritis (OA) is an age-related joint disease affecting millions of individuals worldwide and associated with an extremely high burden largely attributable to disability. To…
Abstract Number: 1077 • ACR Convergence 2020
Glucagon-like Peptide-1 Receptor Agonist Suppresses Muscle Inflammation and Muscle Fiber Death, and Ameliorates Muscle Weakness in Experimental Polymyositis
Mari Kamiya¹, Seon Uk Kim², Jeong Yeon Kim³, Shinsuke Yasuda⁴, Eun Young Lee⁵ and Fumitaka Mizoguchi¹, ¹Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ²Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Jongno-gu, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, ⁴Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Tokyo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Glucocorticoids (GC) are the cornerstone of the treatment for polymyositis (PM). However, the treatment with GC causes GC-induced myopathy, which further deteriorates the muscle…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].